The drug, the lobbyists, the biotechnology firms and insurance companies ratcheted up efforts to offer their two cents and in most cases much, much more influence in-law of medical care that is now working its way through Congress. Many family healths have increased in recent months as an incentive for spending more than $ 1 million, according to the records of inciting the second quarter closed on Monday with the Senate office of public records. AARP, the entry for older Americans who praised the legislation passed by two committees of the house, spent $ 5.3 million in incentive between April 1 and June 30, $ 1.2 million more than the group spent the first quarter. The blue cross and blue of the protective association, a trade association, spent more than $ 2.8 million last quarter, up from $ 1.8 million in the first quarter. The pharmaceutical GlaxoSmithKline invested $ 2.3 million in activities of incitement, an increase of $ 1.8 million reported for the quarter ahead. The pharmaceutical rival Novartis paid out $ 1.8 million, up from $ 1.3 million. And the insurance company Allstate, which spent less than $ 900,000 in March, increased its incentive spending of more than $ 1.5 million in the last three months. Biotechnology companies, like Amgen, Inc. - which reported a $ 3.4 million expense last quarter, up from $ 2.8 million are also bringing in lucrative amounts. But as the debate intensifies in Washington, urging the tabs on some other key organizations shrunk. Pharmaceutical Research and Manufacturers of America, or PHRMA, the trade association of the drug industry, spent $ 6.2 million, down from $ 6.9 million in the first quarter. Pfizer, one of the largest pharmaceutical companies in the world, also cut spending by $ 6.1 million to $ 5.6 million. Still, the two groups spent on quarter of the organizations of medical care the last. American Medical Association, which endorsed the bill of review of the house last week, spent $ 4 million, a full million less than they spent in the fourth quarter of 2008.
